Articles producció científica> Medicina i Cirurgia

Total Tumor Load of mRNA Cytokeratin 19 in the Sentinel Lymph Node as a Predictive Value of Axillary Lymphadenectomy in Patients with Neoadjuvant Breast Cancer

  • Dades identificatives

    Identificador: imarina:9150989
    Autors:
    Pena, Karla B.Kepa, AmillanoCochs, AlbaRiu, FrancescParada, DavidGuma, Josep
    Resum:
    Although sentinel lymph node biopsy (SLNB) has proved to be able to diagnose axillary lymph node status safely and reliably, there is still not enough evidence to suggest that it can be used in patients who have undergone neoadjuvant chemotherapy (NAC) for lymph node-sparing surgery. The present study used molecular approaches to determine whether SLNB can be reliably used in patients who have been treated with NAC before SLN surgery, and whether the total tumor load of the SLN can be used as a predictive factor in axillary lymphadenectomy (ALD). We used one-step nucleic acid amplification (OSNA) to analyze a total of 111 consecutive patients who presented operable invasive breast carcinomas and who had been treated with NAC. SLN was positive in 55 patients and the identification rate was 100%. In 9 of these 55 patients, ALD showed that other lymph nodes were also involved. In all of the other 46 patients, the only lymph node to be identified as positive was SLN. Metastasis was not found in any of the axillary lymph nodes in the isolated tumor cell group. The total tumor load, defined as the amount of cytokeratin 19 mRNA copy numbers in all positives SLN (copies/mu L), showed three risk groups related to the possibility of positive non-sentinel nodes. OSNA is a diagnostic technique that is highly sensitive, specific, and reproducible and it can be used to analyze sentinel lymph nodes after NAC. Total tumor load may be able to help predict additional metastases in axillary lymphadenectomy.
  • Altres:

    Autor segons l'article: Pena, Karla B.; Kepa, Amillano; Cochs, Alba; Riu, Francesc; Parada, David; Guma, Josep;
    Departament: Medicina i Cirurgia
    Autor/s de la URV: Gumà Padró, José / Parada Dominguez, David / Peña Gonzalez, Karla Beatriz / Riu Ferrando, Francisco Pedro
    Paraules clau: Very elderly Tumor volume Tumor marker Tumor burden Trastuzumab Total tumor load Technetium 99m Taxane derivative Surgery Sentinel lymph node biopsy Sentinel lymph node Rna, messenger Prospective studies Predictive value of tests Predictive value Pertuzumab Pathology Paget nipple disease Paclitaxel Osna Nucleic acid amplification Neoadjuvant therapy Neoadjuvant chemotherapy Middle aged Messenger rna Mastectomy Major clinical study Lymphatic metastasis Lymph node metastasis Lymph node excision Lymph node dissection Krt19 protein, human Keratin-19 Humans Human tissue Human Gold standard Genetics Gene dosage Female Doxorubicin Docetaxel Diagnostic test accuracy study Diagnostic accuracy Descriptive research Cytokeratin 19 Cyclophosphamide Correlational study Controlled study Cohort analysis Cell isolation Carcinoma, ductal, breast Carcinoma cell Carboplatin Cancer size Cancer patient Cancer adjuvant therapy Breast tumor Breast neoplasms Breast carcinoma Breast cancer Breast Biomarkers, tumor Axillary lymphadenectomy Axillary lymph node dissection Axilla Article Antineoplastic agent Anthracycline derivative Aged, 80 and over Aged Adult Adjuvant therapy
    Resum: Although sentinel lymph node biopsy (SLNB) has proved to be able to diagnose axillary lymph node status safely and reliably, there is still not enough evidence to suggest that it can be used in patients who have undergone neoadjuvant chemotherapy (NAC) for lymph node-sparing surgery. The present study used molecular approaches to determine whether SLNB can be reliably used in patients who have been treated with NAC before SLN surgery, and whether the total tumor load of the SLN can be used as a predictive factor in axillary lymphadenectomy (ALD). We used one-step nucleic acid amplification (OSNA) to analyze a total of 111 consecutive patients who presented operable invasive breast carcinomas and who had been treated with NAC. SLN was positive in 55 patients and the identification rate was 100%. In 9 of these 55 patients, ALD showed that other lymph nodes were also involved. In all of the other 46 patients, the only lymph node to be identified as positive was SLN. Metastasis was not found in any of the axillary lymph nodes in the isolated tumor cell group. The total tumor load, defined as the amount of cytokeratin 19 mRNA copy numbers in all positives SLN (copies/mu L), showed three risk groups related to the possibility of positive non-sentinel nodes. OSNA is a diagnostic technique that is highly sensitive, specific, and reproducible and it can be used to analyze sentinel lymph nodes after NAC. Total tumor load may be able to help predict additional metastases in axillary lymphadenectomy.
    Àrees temàtiques: Medicina ii Medicina i Matemática / probabilidade e estatística Genetics (clinical) Genetics & heredity Genetics Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência da computação Biotecnología Biodiversidade
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Adreça de correu electrònic de l'autor: franciscopedro.riu@urv.cat karlabeatriz.pena@urv.cat david.parada@urv.cat jose.guma@urv.cat
    Identificador de l'autor: 0000-0001-7541-9832
    Data d'alta del registre: 2024-07-27
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://www.mdpi.com/2073-4425/12/1/77
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referència a l'article segons font original: Genes. 12 (1): 1-10
    Referència de l'ítem segons les normes APA: Pena, Karla B.; Kepa, Amillano; Cochs, Alba; Riu, Francesc; Parada, David; Guma, Josep; (2021). Total Tumor Load of mRNA Cytokeratin 19 in the Sentinel Lymph Node as a Predictive Value of Axillary Lymphadenectomy in Patients with Neoadjuvant Breast Cancer. Genes, 12(1), 1-10. DOI: 10.3390/genes12010077
    DOI de l'article: 10.3390/genes12010077
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2021
    Tipus de publicació: Journal Publications
  • Paraules clau:

    Genetics,Genetics & Heredity,Genetics (Clinical)
    Very elderly
    Tumor volume
    Tumor marker
    Tumor burden
    Trastuzumab
    Total tumor load
    Technetium 99m
    Taxane derivative
    Surgery
    Sentinel lymph node biopsy
    Sentinel lymph node
    Rna, messenger
    Prospective studies
    Predictive value of tests
    Predictive value
    Pertuzumab
    Pathology
    Paget nipple disease
    Paclitaxel
    Osna
    Nucleic acid amplification
    Neoadjuvant therapy
    Neoadjuvant chemotherapy
    Middle aged
    Messenger rna
    Mastectomy
    Major clinical study
    Lymphatic metastasis
    Lymph node metastasis
    Lymph node excision
    Lymph node dissection
    Krt19 protein, human
    Keratin-19
    Humans
    Human tissue
    Human
    Gold standard
    Genetics
    Gene dosage
    Female
    Doxorubicin
    Docetaxel
    Diagnostic test accuracy study
    Diagnostic accuracy
    Descriptive research
    Cytokeratin 19
    Cyclophosphamide
    Correlational study
    Controlled study
    Cohort analysis
    Cell isolation
    Carcinoma, ductal, breast
    Carcinoma cell
    Carboplatin
    Cancer size
    Cancer patient
    Cancer adjuvant therapy
    Breast tumor
    Breast neoplasms
    Breast carcinoma
    Breast cancer
    Breast
    Biomarkers, tumor
    Axillary lymphadenectomy
    Axillary lymph node dissection
    Axilla
    Article
    Antineoplastic agent
    Anthracycline derivative
    Aged, 80 and over
    Aged
    Adult
    Adjuvant therapy
    Medicina ii
    Medicina i
    Matemática / probabilidade e estatística
    Genetics (clinical)
    Genetics & heredity
    Genetics
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Ciência da computação
    Biotecnología
    Biodiversidade
  • Documents:

  • Cerca a google

    Search to google scholar